BioSpace News Archive

CanSino Biologics Inc. today announced that The Lancet[1] published its Phase III clinical trial results on the safety and efficacy of its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (“Ad5-nCoV”, trade name: Convidecia™).

Covalon Technologies Ltd. today announced that Danny Brannagan , its Chief Financial Officer, will be stepping down in January 2022 to pursue other endeavours.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 23,400 shares of the Company’s common stock at an exercise price per share of $44.59, which was the closing price on December 23, 2021.

The financing will enable Lysogene to accelerate the development of its gene therapy platform.

Microbix Biosystems Inc. announces receipt of a follow-on order of C$ 4.7 million for its viral transport medium (generically known as “ VTM ” and branded “ DxTM™ ” by Microbix). DxTM is a sample-collection device that is essential for PCR-based testing for viruses that cause COVID-19 disease.

aTyr Pharma, Inc. today announced the appointment of Danielle Campbell to Vice President, Human Resources.

Laekna was invited by NewYorkBIO and the New York Stock Exchange (NYSE) to present, as an emerging biotech company at the “Emerging Company Showcase” that was held earlier this month in New York.

WestVac BioPharma Co., Ltd. has achieved a significant progress in the second generation COVID-19 vaccine against the Omicron mutant strain.

Accutar Biotechnology, Inc. , a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Innovent Biologics, Inc. today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for sintilimab plus bevacizumab biosimilar injection.